Noctrix Health is currently negotiating to bring its Nidra device to the British market. The medical tool employs electrical pulses to mitigate the symptoms of Restless Legs Syndrome (RLS), providing a non-drug alternative for patients who struggle with sleep and mobility.
The risk of gambling addiction and suicidal thoughts from dopamine agonists
For decades, the primary pharmacological defense against chronic Restless Legs Syndrome has been dopamine agonists, which mimic the brain's natural chemicals to regulate movement. However, as the report says, there is mounting evidence that these specific medications can trigger severe psychiatric side effects, including obsessive sexual desires, gambling addiction, and suicidal ideation.
The danger is compounded by a phenomenon known as augmentation, where the medication actually causes symptoms to worsen or appear earlier in the day.. For the one in five sufferers whose cases are classified as severe , the failure of these drugs can lead to a total collapse of mental health and professional stability. Dr Julian Spinks, a GP and chair of RLS-UK, noted that for these high-severity patients, even a modest reduction in symptoms is considered a significant victory.
An 8.4-point symptom reduction for 232 trial patients
The Nidra device by Noctrix Health attempts to bypass the bloodstream entirely by stimulating nerve pathways below the knees for 30-minute sessions. According to the source, this process mimics the nerve activity associated with walking, which naturally eases the "crawling" sensations typical of RLS.
A study published this year involving 232 patients—all of whom had RLS that was not adequately controlled by medication—showed promising results . The data indicates that the number of days per week patients experienced symptoms dropped from 6.1 to 4.8, while average symptom scores improved by 8.4 points. furthermore, nearly 80 percent of the participants achieved a clinically meaningful benefit, and roughly 20 percent were able to reduce their reliance on medication without a return of symptoms.
The £6,000 barrier for 6,500 US users
While the clinical results are encouraging, the accessibility of the Nidra device remains a primary concern. In the United States, where more than 6,500 patients are already using the technology, the device is sold for approximately £6,000.
This price point creates a steep barrier for the general population, particularly since RLS affects up to one in ten peeople and is more prevalent among women.. If Noctrix Health brings the device to the UK, the central question will be whether it is positioned as a private-pay luxury or if it can be integrated into the National Health Service (NHS) to reach the one in five sufferers who are unresponsive to traditional drug treatments.
The missing placebo group in the Noctrix Health study
Despite the reported success of the Nidra device, a critical gap exists in the current clinical evidence. The study involving 232 patients lacked a placebo group, meaning researchers cannot definitively prove that the improvements in sleep quality and symptom frequency were caused by the electrical pulses rather than a placebo effect.
Additionally, while the reported side effects—such as skin irritation and general discomfort—were mild, the lack of a control group leaves the true efficacy of the device open to debate. Until a double-blind study is conducted, the medical community may remain cautious about replacing established, albeit flawed, pharmaceutical protocols with this new hardware.
Comments 0